Avalo Therapeutics names Kevin Lind to board of directors

Avalo Therapeutics Inc. (NASDAQ: AVTX) appointed Kevin R. Lind to its board of directors, the Wayne, Pennsylvania-based biotechnology company announced.

Lind brings more than 20 years of experience in capital markets, strategy and business development. He most recently served as president, chief executive officer and board member of Longboard Pharmaceuticals, leading the company through its $2.6 billion acquisition by H. Lundbeck A/S in 2024.

Prior to Longboard, Lind was executive vice president and chief financial officer at Arena Pharmaceuticals, where he played a role in the company's turnaround and the spinout of Longboard in 2020. Over his career, Lind has raised more than $1 billion in capital for biotechnology companies.

Avalo is currently conducting a Phase 2 trial called LOTUS for its lead drug candidate AVTX-009 in hidradenitis suppurativa, with topline data expected mid-2026. The company focuses on developing treatments targeting interleukin-1β for immune-mediated inflammatory diseases.

"Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial," said Michael Heffernan, chairman of the board, according to the company's statement.

Lind currently serves as chairman of the board of Apnimed Inc. He holds a bachelor's degree in biological sciences from Stanford University and an MBA from UCLA Anderson School of Management. He began his career in investment banking at Lehman Brothers before joining TPG, where he focused on healthcare investing.

You May Also Be Interested In

• Cosmos Health signs Saudi distribution deal for supplement line
• FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
• RenovoRx receives USPTO notice of allowance for RenovoCath patent